Search Results (89)

Although Atractylodes macrocephala Koidz. (AM) exhibits various pharmacological properties, its molecular effects and active constituents regarding anagen entry and physiological hair cycle progression remain uncharacterized. This study aimed to investigate the hair growth-promoting efficacy of AM and identify its bioactive compounds and underlying molecular mechanisms. We evaluated AM extract using human dermal papilla cells (DPCs) and a synchronized depilation-induced C57BL/6 mouse model, employing RT-PCR, Western blotting, immunofluorescence, and SwissADME-based pharmacokinetic profiling. AM significantly enhanced DPC proliferation and migration while upregulating paracrine factors (HGF, VEGF, and FGF7). Mechanistically, AM activated Akt, ERK, and p38 MAPKs, leading to GSK3β phosphorylation (Ser9) and subsequent β-catenin stabilization. In vivo, oral AM (60 mg/kg) markedly accelerated the telogen-to-anagen transition, increasing dermal thickness, follicle count, and hair shaft quality without systemic toxicity. Furthermore, cell-based screening and SwissADME prioritized atractylenolide I and III as the chief bioactive sesquiterpenoids driving DPC activation. In conclusion, AM and its key atractylenolides promote anagen entry and hair regrowth, in association with GSK3β phosphorylation and β-catenin stabilization, representing promising natural candidates for promoting physiological hair cycle progression. Full article

Melatonin, a methoxyindole synthesized by the pineal gland, is secreted in response to photoperiodic cues relayed from the retina through an endogenous circadian oscillator within the suprachiasmatic nucleus. Consequently, melatonin secretion regulates the circadian rhythm. Melatonin has been reported to have antioxidant, photoprotective, anti-inflammatory, anticancer, and wound-healing properties. It has also been reported to promote hair growth, although the underlying mechanisms remain unclear. In this study, we explored the potential molecular mechanisms of melatonin-induced hair growth by using an in vivo C57BL/6 mouse model. We observed morphological changes in the dorsal area and changes in the hair cycle and anagen induction were observed through hematoxylin–eosin staining. The molecular mechanisms were explored using Western blotting and immunofluorescence assay. Our findings indicate that topical melatonin promotes anagen entry and hair regrowth in C57BL/6 mice, accompanied by the modulation of Wnt/β-catenin-related signaling proteins. The decrease in grayscale value, increase in hair length and skin thickness and histological change in hair follicles in the melatonin-treated group indicated hair regrowth in the dorsal skin of mice. Moreover, the expression of the Wnt/β-catenin pathway was remarkably regulated. These findings further our understanding of the molecular mechanisms underlying topical melatonin-induced hair growth. Full article

This study aimed to optimize the extraction and purification of TSG-enriched Polygonum multiflorum extract and evaluate its therapeutic potential against androgenetic alopecia. P. multiflorum Thunb. has long been used in traditional Chinese medicine to promote hair growth and preserve hair pigmentation. Microwave-assisted extraction (MAE) was optimized to obtain a 2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside (TSG)-enriched P. multiflorum extract (PME). The crude extract was further purified by medium-pressure liquid chromatography and semipreparative high-performance liquid chromatography. Phytochemical profiling by HPLC demonstrated a 3.75-fold increase in TSG content, from 22,770.0 ± 815 ppm to 85,387.5 ± 192 ppm, and the identity of the enriched TSG was confirmed by LC–MS and ¹H NMR spectroscopy. PME exhibited potent dose-dependent inhibition of 5α-reductase activity, reaching 92.7% inhibition at 1 μg/mL, comparable to that of finasteride. In a testosterone (TES)-induced androgenetic alopecia (AGA) mouse model, PME markedly accelerated hair regrowth and increased both the number and size of hair follicles. Mechanistically, PME suppressed the conversion of TES to dihydrotestosterone (DHT) through 5α-reductase inhibition and promoted GSK3β inactivation, β-catenin stabilization, and nuclear translocation, indicating activation of the Wnt/β-catenin signaling pathway. Consequently, the expression of hair growth-related proteins, including Ki67 (1.98-fold), epidermal growth factor (EGF, 1.54-fold), insulin-like growth factor-1 (IGF-1, 1.21-fold), and vascular endothelial growth factor (VEGF, 1.34-fold), was significantly upregulated. These findings demonstrate, for the first time, that TSG-enriched PME obtained through optimized MAE and chromatographic purification promotes hair regeneration through a dual mechanism involving 5α-reductase inhibition and Wnt/β-catenin activation, highlighting its potential as a natural therapeutic candidate for androgenetic alopecia. Full article

Background: Lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) are primary cicatricial alopecias with no FDA-approved treatments and a limited evidence base for any intervention. Alopecia areata (AA), while better studied, similarly lacks a well-tolerated, locally acting non-pharmacologic option. The 308 nm excimer laser is established in inflammatory dermatoses, yet its role in hair loss conditions has not been systematically characterized. This review provides an updated appraisal of the AA evidence base and the first systematic appraisal of excimer therapy in LPP and FFA. Methods: We searched PubMed/Medline, Embase, Web of Science, Scopus, and Cochrane CENTRAL and synthesized findings narratively, given substantial heterogeneity across included studies. Results: In total, 33 studies reporting 634 unique patients met the inclusion criteria across AA subtypes (patchy/localized, totalis, universalis, ophiasic, and pediatric), LPP, and FFA. Most evidence (30/33 studies, 613/634 patients) pertains to AA, where excimer therapy produced meaningful hair regrowth in a large proportion of patients. Cicatricial data was more limited (3/33 studies, 21/634 patients). LPP data suggest improvement in inflammatory symptoms; FFA results were mixed. Adverse effects were mild and transient, primarily erythema and hyperpigmentation. Conclusions: The use of 308 nm excimer therapy may be a well-tolerated non-pharmacologic option when pharmacologic therapy is contraindicated, poorly tolerated, or inadequately effective, though limited evidence, especially for LPP and FFA, warrants further investigation across these and other conditions not yet studied. Full article

Background: Gestational iron requirements may lead to maternal iron deficiency, increasing susceptibility in offspring. In mice, maternal iron deficiency induces hair loss in pups, but mechanisms remain poorly characterized. Objective: This study investigates mechanisms underlying maternal iron deficiency-induced abnormal hair growth and the impact of iron supplementation on pups’ hair development. Methods: Pregnant C57BL/6J mice (nine-week-old, second week of gestation) were randomly assigned to a standard AIN-76 diet (control, CTRL) or an iron-deficient AIN diet (ID) until parturition and weaning. Offspring were maintained on the same diet as their mothers. At six weeks, hair loss was examined in one set (CTRL1 and ID), while the remaining were transitioned to an iron-replete AIN-76 diet (CTRL2 and IDN) for two additional weeks. An in vitro study with human follicle dermal papilla cells (HFDPC) via deferoxamine (DFO) treatment was performed. Results: ID offspring exhibited truncal hairlessness, reduced body size, and abnormal follicular morphology compared to CTRL1, while IDN demonstrated hair regrowth comparable to CTRL2. ID skin tissues had reduced Wnt/β-catenin signaling, elevated oxidative stress markers, and activation of caspase-3, nuclear factor kappa B (NF-κB), and transforming growth factor-beta (TGF-β) signaling, all reversed by iron supplementation. DFO-treated HFDPCs demonstrated increased cellular and mitochondrial reactive oxygen species (ROS), diminished Wnt/β-catenin signaling, activation of caspase-3, NF-κB, and TGF-β signaling pathways. N-acetylcysteine pretreatment abrogated DFO-induced alterations in Wnt/β-catenin signaling and apoptosis, suggesting ROS mediates iron deficiency-induced hair loss. Conclusions: Early iron deficiency may have impaired hair growth through increased ROS production, reduced Wnt/β-catenin signaling, and enhanced apoptotic signals, while postnatal iron supplementation could reverse these abnormalities. Full article

Collagen peptides have been widely studied for their beneficial effects on skin health; however, their potential role in hair growth remains insufficiently explored. This study aimed to investigate the effects of orally administered low-molecular-weight fish collagen peptide (SH-GT) on hair regrowth and its underlying mechanisms in a hair-removed C57BL/6J mouse model. Mice were administered SH-GT (100, 300, or 600 mg/kg body weight) or a positive control (Pansidil, 400 mg/kg) daily for 28 days. SH-GT significantly enhanced hair regrowth, as evidenced by the increased hair growth area. Histological analysis revealed increased dermal thickness and visible hair follicle structures in SH-GT-treated groups. At the molecular level, SH-GT upregulated proliferation-related proteins, including PCNA and Cyclin D1, and activated Wnt/β-catenin signaling. In addition, SH-GT enhanced PI3K/Akt/mTOR signaling, suggesting improved cellular growth and survival. Conversely, SH-GT suppressed hair growth inhibitory pathways by reducing BMP4 expression and decreasing Smad phosphorylation. Furthermore, SH-GT increased the mRNA expression of growth factors such as IGF-1, HGF, VEGF, EGF, and FGF7. In conclusion, SH-GT promotes hair regrowth by simultaneously activating proliferation-related signaling pathways and suppressing inhibitory mechanisms, thereby improving the dorsal skin microenvironment associated with hair regrowth. These findings suggest that SH-GT may serve as a promising functional ingredient for improving hair growth. Full article

Background: Despite the rise of endoscopic approaches, the direct brow lift remains one of the most effective procedures for correcting brow ptosis for both functional and cosmetic indications. It continues to offer superior control when correcting brow shape, height, and asymmetry. However, visible scarring remains a concern. This systematic review was conducted to synthesize recent evidence on strategies that minimize visible scarring in direct brow lift surgery. Methods: A systematic literature search was performed to retrieve English-language publications from the past decade, discussing scar-minimization strategies in direct brow lift. A total of 124 records were identified through database searches in Ovid MEDLINE and Embase. Records were screened manually according to predetermined criteria, and those not in English, not addressing scarring, or not focused on direct brow lift were excluded. After this process, ten publications were included in the final qualitative synthesis. Results: The qualitative synthesis of all included publications (together comprising data on approximately 900 patients) revealed several strategies for scar minimization. (1) Incision beveling: A shallow cranially directed bevel between 20° and 45° preserves brow hair follicles and allows hair regrowth through the scar, providing natural camouflage. (2) Undermining: Gentle subcutaneous undermining in a limited 1–2 cm field, while preserving subcutaneous fat, allows tension-free advancement and maintains brow volume. (3) Periosteal suspension: Anchoring the mobilized brow flap to the frontal periosteum redistributes tension away from the dermal closure, maintaining elevation and improving scar quality. (4) Layered closure: Two- or three-layered wound closure with deep dermal anchoring and fine everting skin sutures minimizes dermal traction and scar widening. (5) Adjunctive measures: Evidence for topical silicone gel was inconclusive, whereas postoperative laser therapy and perioperative neuromodulator use demonstrated improved scar appearance. Across studies, outcomes were consistent, with high patient satisfaction, inconspicuous scars in over 85% of cases, and low complication or revision rates. Conclusions: Direct brow lift has historically been criticized for conspicuous scarring, contributing to the popularity of endoscopic techniques. Nevertheless, the traditional direct brow lift remains a fundamental skill in the oculofacial plastic surgeon’s armamentarium, offering unmatched accuracy in brow repositioning, reliability, and symmetry. Contemporary evidence demonstrates refinements that can markedly minimize scar visibility. This systematic review and qualitative synthesis allow us to continue to refine and improve our techniques to minimize scarring in direct brow lift to the benefit of our patients. Full article

Introduction: Alopecia areata (AA) is a chronic immune-mediated disorder characterized by non-scarring hair loss and a significant psychosocial burden. Ritlecitinib, a selective Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinase inhibitor, has recently emerged as a targeted systemic therapy for moderate-to-severe AA. While randomized clinical trials have demonstrated its efficacy, real-world evidence remains limited and heterogeneous. Methods: A structured narrative review was conducted to summarize current evidence on ritlecitinib in AA, with a focus on real-world outcomes. A comprehensive search of PubMed/MEDLINE, Scopus, Embase, and Cochrane Library was performed up to March 2026 using predefined keywords. Eligible studies included real-world observational studies, case series, and post hoc analyses of randomized controlled trials reporting clinical outcomes. Two independent reviewers performed study selection. Results: A total of 14 studies were included. Clinical trial analyses suggested sustained efficacy over time, with progressive improvement in Severity of Alopecia Tool (SALT) scores up to 24 months. Real-world studies reported clinically meaningful hair regrowth across diverse populations, including severe, pediatric, and treatment-experienced patients. Response rates increased over time, with a proportion of patients achieving SALT ≤ 20 or ≥80% improvement. Lower baseline severity and shorter disease duration were reported in several studies as potential factors associated with a better response. Safety profiles were favorable, with predominantly mild adverse events. Discussion: Ritlecitinib shows consistent effectiveness and acceptable safety in both clinical trials and real-world settings. Treatment response appears progressive and heterogeneous, supporting the importance of early intervention and adequate treatment duration. Further large-scale and long-term real-world studies are needed to better define predictors of response and optimize patient selection. Full article

Skin and its appendages form an integrated system of ectodermal mini-organs that rely on Wnt signaling for lifelong homeostasis and regeneration; yet, the pathway operates in a highly organ-specific manner in each compartment. In interfollicular epidermis, the Wnt activity is spatially graded, thus maintaining the balance between basal progenitor proliferation and terminal differentiation. The hair follicle is governed by an intrinsic oscillator based on cross-regulation between Wnt and BMP signaling, providing a cell-autonomous layer of control over hair cycle dynamics. Finally, the nail organ is characterized by the spatial compartmentalization of Wnt activity, with a distal matrix activation zone supported by specialized mesenchymal niche cells that sustain continuous nail plate growth and coordinate the digit tip regeneration. Understanding these divergent regulatory architectures provides a conceptual framework for targeted regenerative strategies aimed at enhancing repair in skin and its appendages. Therefore, in this review, we synthesize recent molecular studies on Wnt signaling in the adult skin, hair follicles, and nail mini-organs, highlighting appendage-specific features that underlie their distinct regenerative capacities. We further discuss how dysregulated Wnt signaling contributes to skin, hair, and nail pathologies such as alopecia, chronic wounds, excessive scarring, skin cancer, and nail deformations, and summarize the emerging strategies that target Wnt pathway to therapeutically enhance hair regrowth, wound repair, cancer treatment, and digit tip regeneration. Full article

Hair serves essential functions, including mechanical sensing, head protection, and body temperature regulation, while also playing a significant role in human aesthetics. However, factors such as hormonal imbalances, autoimmune disorders, infections, and psychological stress contribute to the widespread issue of hair loss, particularly among the elderly, adversely affecting self-confidence and self-esteem. Although treatments such as minoxidil, finasteride, and dutasteride have received regulatory approval, their associated side effects, such as sexual dysfunction, neuropsychiatric issues, and cardiovascular symptoms, can impede patient recovery. While follicular unit transplantation and stem cell therapy show promising outcomes, they are not suitable for all types of hair disorders. Short peptides that mimic intracellular signals and exhibit diverse biological effects have emerged as a promising approach for stimulating hair regrowth. By combining different formulations and nanosystems, the limitations of short peptides can be effectively addressed. This review systematically summarizes recent advances in peptide-based treatments for hair loss, highlighting their advantages and limitations. Full article

Background: Alopecia areata is an autoimmune disorder characterized by nonscarring hair loss, which can progress to alopecia totalis or universalis. While JAK inhibitors have shown efficacy in severe cases, evidence in pediatric and adolescent populations remains limited. This study evaluated the efficacy and safety of upadacitinib in pediatric patients with alopecia totalis and subtotalis. Methods: This is a retrospective case series that included eight patients aged 9 to 14 years treated with upadacitinib 15 mg daily and followed for up to two years. Clinical response, treatment duration, adverse effects, and laboratory results were monitored. Results: All patients demonstrated clinical improvement, with most achieving complete or near-complete regrowth of scalp, eyebrow, and eyelash hair. The median regrowth time was 3 months. Mild acne was observed in two patients; no serious side effects occurred. Conclusions: In this case series, upadacitinib was associated with encouraging clinical responses and was well-tolerated by most of our patients; however, larger-scale studies are needed to confirm its efficacy and long-term safety. Full article

Hair loss, or alopecia, constitutes a significant and prevalent concern affecting individuals worldwide. Despite the availability of numerous commercial solutions, many individuals continue to experience substantial psychological distress, leading to adverse impact on personal relationships, social interactions, and occupational performance. The limitations of conventional treatments, such as oral medication with potential systemic side effects and topical applications with localized adverse events, have driven the exploration of alternative therapies. Emerging localized injectable treatments for hair regrowth (PRP, stem cells, exosomes) offer a promising avenue for addressing this persistent issue. These injectable therapies hold the potential to minimize the systemic side effects often associated with oral medications, while also mitigating the localized adverse events that can arise from topical applications. This narrative review provides a comprehensive overview of the medical state-of-the-art in off-label injectable hair regrowth treatments, delving into the diverse range of available options. A critical component of this narrative review involves a thorough evaluation of relevant clinical studies, assessing the efficacy and safety profiles of these emerging therapies. Furthermore, detailed attention is given to injection techniques and administration protocols, crucial factors in optimizing treatment outcomes. These evolving therapies represent a significant advancement in the field of scalp regenerative medicine. By stimulating hair follicle reactivation, these treatments aim to promote sustained and natural hair growth, providing individuals with more effective and durable solutions. The enhanced safety profiles of these injectable therapies, compared to conventional systemic pharmacological treatments (minoxidil, finasteride), offer a substantial improvement in patient care, addressing a widespread clinical need. Full article

Background: Hyperbaric oxygen therapy (HBOT) has regenerative effects in various tissues, but its impact on hair follicles is unclear. This preliminary study evaluated HBOT-induced changes in hair and scalp characteristics in healthy adults. Methods: Nine healthy volunteers completed 50 HBOT sessions over three months (2.0 ATA, 100% oxygen, 90 min per session). Objective assessments included follicle density, hairs per follicle, hair volume, and shaft thickness using the Becon phototrichogram system. Subjective evaluations were conducted via a 7-point Likert questionnaire on scalp appearance, hair density, thickness, growth, and shedding. Pre- and post-treatment data were compared using paired statistical tests. Results: Positive trends were observed in follicle density (61.3→66.8 counts/cm²), hairs per follicle (1.24→1.33), and hair volume (24.9→27.7%), though not statistically significant. Hair shaft thickness decreased significantly (0.18→0.10 mm, p = 0.011), consistent with early anagen-phase regrowth. Subjective assessments showed significant improvements across all domains (p < 0.05). Scalp imaging visually supported these findings. Conclusions: HBOT may enhance hair follicle activation and scalp health in healthy adults. These preliminary findings justify further controlled studies to explore HBOT as a non-pharmacological approach to hair regeneration. Full article

Background: Regenerative therapies have emerged in recent years. In particular, their utility in managing androgenetic alopecia—the most prevalent hair loss condition worldwide, affecting up to half of adults—is an active area of research. Navigating this space can be challenging for physicians due to widespread commercialization, lack of high-quality evidence, and an evolving regulatory landscape. Objective: To critically review recently published evidence (2020–2025) on platelet-rich plasma, photobiomodulation, stem cells, and exosomes for the treatment of androgenetic alopecia. Methods: A scoping review was conducted using PubMed, Embase (Ovid) and the Cochrane Controlled Register of Trials in February and November of 2025. Combination therapies were excluded. Results and Conclusions: Platelet-rich plasma is the most studied modality, with emerging investigations into newer formulations such as leukocyte-rich and pure platelet-rich plasma. However, recent studies are limited by inconsistent reporting of cellular composition, short follow-up durations, and a lack of comparative data on treatment protocols. The efficacy of photobiomodulation as a monotherapy remains debated, with inconsistent reporting of device parameters. Stem cells and exosomes show promising, though still limited, clinical evidence in inducing hair regrowth. Standardization of these therapies is crucial, with emphasis on transparency, reproducibility, and patient safety. Full article

Background: Topical minoxidil remains the only FDA-approved treatment for hair loss, yet its clinical efficacy is compromised by organic-solvent-induced scalp irritation and poor patient adherence. This study aimed to evaluate natural illite as a carrier for minoxidil and to explore its potential hair-growth-promoting mechanisms. Methods: Thermal–acid-modified illite was engineered as a spray-dried, hydroalcohol-free minoxidil carrier for topical application. Hair regrowth efficacy was assessed in C57BL/6 mice via a 14-day depilation model. Mechanisms were elucidated via RNA-seq, Ki67/TUNEL immunofluorescence, and p-STAT3 immunohistochemistry. Results: Modified illite resulted in a 4.2-fold surface area increase and successful minoxidil loading. The minoxidil/illite formulation demonstrated efficacy equivalent to that of free minoxidil while also eliminating solvent toxicity. Mechanistic analysis revealed that illite functions as an active carrier: both the illite-alone and minoxidil/illite-treated groups exhibited increased Ki67⁺ proliferation and reduced TUNEL⁺ apoptosis. Transcriptomic profiling demonstrated dual mechanisms—enrichment of Myc proliferation pathways and suppression of IL-6 inflammatory signaling (p < 0.001)—with reduced p-STAT3 expression confirmed by immunohistochemistry. Conclusions: These findings suggest that an illite-based carrier can enable topical delivery of minoxidil with preserved efficacy and that illite itself exhibits intrinsic hair-growth-promoting activity via anti-inflammatory and pro-proliferative mechanisms, which may help alleviate adherence barriers associated with conventional topical alopecia therapy. Full article